Zhu Chenchen (pseudonym) is a 20-year-old young man who, in March 2019, was in his prime when he suffered from DLBCL (diffuse large B-cell lymphoma).

In November 2020, Zhu Chenchen arrived at Evergrande International Hospital located in the pilot area of Lecheng. Doctor, I have added many groups, including the communication group for lymphoma patients' family members and the communication group for lymphoma recurrence and difficult to treat patients. Patients all say that over 90% of them are metastatic cancer, which is very dangerous. "Zhu Chenchen said," I live a regular life and do not smoke or drink, which is unfair in heaven

Pessimism, procrastination, selfishness, fear, isolation, destructive psychology, self abandonment, whimsical thinking, and cynicism. These are the nine psychological disorders of patients. If you follow these nine sins, even immortals cannot save you. "The doctor patiently explained to Mr. Zhu, Cancer is actually fair. Cancer cells are present in everyone, but it's just a matter of gathering and not gathering. As the body weakens and the immune system weakens, cancer cells will gather and spread everywhere in the body

In response to Mr. Zhu's condition, Evergrande Hospital immediately established an expert group after the initial interview. After reviewing the medical records, it was found that his condition was still spreading after receiving six line treatments including R-IGEV, local radiotherapy, autologous stem cell transplantation, lenalidomide+rituximab, bendamustine combined with navumab, and vituximab.

What's unfair is one's own immune system, young man. Cheer up, you're young and have a strong physical foundation. Lymphoma like yours is not uncommon. Celebrities such as Luo Jing and Li Yu have all passed away early due to lymphoma, and many people believe that lymphoma means the end of life, but that's not the case. Lymphoma is not a terminal disease! "The doctor encouraged him to actively face life and continue fighting.

In fact, since the application of the targeted drug CD20 monoclonal antibody for B-cell lymphoma, the cure rate of lymphoma has significantly improved. However, nearly half of the patients still belong to recurrent or refractory conditions, and their treatment needs have not been met, such as Zhu Chenchen.

Until the birth of a new drug, Polatuzumab vedotin (Pola), its unique mechanism of action enhanced its anti-tumor efficacy. After the introduction of Pola, a series of clinical studies have been carried out, and the remission rate of Pola in the treatment of relapsed and refractory DLBCL patients exceeds 50%.

Although Pola has not yet been approved for listing in China, Evergrande International Hospital can apply for priority use of Pola's new drugs based on the policy advantage of "licensed medical treatment, first trial" in the Lecheng pilot area.

In November 2020, after completing relevant examinations and finding no obvious contraindications for treatment, Zhu Chenchen began using Pola in combination with rituximab and bendamustine for treatment. After 2 cycles of follow-up, the condition partially alleviated. Currently, the treatment is effective and well tolerated, and we are continuing treatment. This is also his first improvement after failing his sixth line treatment.

Disease is terrifying, but even more terrifying is that because of it, one not only loses hope for life, but also loses fighting spirit. This young man in his early twenties regained his confidence in fighting in Lecheng.

Diffuse large B-cell lymphoma (DLBCL) is the most common histological type of non Hodgkin's lymphoma (NHL) and an invasive hematological malignancy. Approximately 40% of untreated DLBCL patients experience recurrence after standard treatment, and once recurrence occurs, subsequent treatment options are limited and the prognosis is poor.

Polivy ® Polatuzumab Vedotin is a pioneering antibody drug conjugate (ADC) targeting CD79b. In the United States and the European Union, Polivy ® Both have been granted orphan drug qualifications for the treatment of DLBCL, and have been granted breakthrough drug qualifications (BTD) and priority drug qualifications (PRIME), respectively.

Research shows that Polivy ® The effective rate of treating adult patients with recurrent or refractory diffuse large B-cell lymphoma with the combination of bendamustine and rituximab (Pola-BR) is 2.2 times higher than that of bendamustine combined with rituximab (BR). The complete response rate is significantly increased (CR: 40% vs 18%), the overall survival time is more than doubled (median OS: 12.4 months vs 4.7 months), and the duration of response is significantly prolonged (median DOR: 10.3 months vs 4.1 months; HR=0.44), Reduce the risk of death by 58%.